- Details
- Ashish Kamat is joined by Patrick Lewicki to discuss the recent publication on the underutilization of Blue Light Cystoscopy (BLC) in the United States. Studying the use of BLC in the Premier Healthcare Database, the findings demonstrate a low level of BLC use despite guideline recommendations and evidence demonstrating the benefit for its use in the management of non-muscle invasive bladder cance...
|
- Details
- In this UroToday journal club, Christopher Wallis and Zachary Klaassen highlight a European Urology Focus publication entitled Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States. Blue light cystoscopy (BLC) for the management of nonmuscle invasive bladder cancer (NMIBC) is an evidence- and guideline-supported intervention that has been shown to increase cancer detect...
|
- Details
- In this 2021 LUGPA CME presentation, Michael O’Donnell discusses intravesical therapies for non-muscle invasive disease. He covers the background of indications for intravesical therapy, managing recurrent non-muscle invasive bladder cancer (NMIBC) including BCG failures and BCG unresponsiveness. Biographies: Michael A. O’Donnell, MD, Richard D. Williams Professor & Director of Urologic Oncology,...
|
- Details
- Joining Ashish Kamat is Arjun Balar, both experts in the field of bladder cancer and each closely involved with the FDA approval of pembrolizumab in the BCG-unresponsive bladder cancer population. Dr. Balar outlines the history of the drug, how the study which led to the FDA approval in NMIBC was designed. Dr. Balar also expands in his approach to counseling his patients who are considering pembro...
|
- Details
- Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...
|
- Details
- Yair Lotan discusses the advancements in the ability to detect bladder cancer and bladder cancer recurrence in the clinic with blue light cystoscopy. Until recently, the technology was only available in the OR but now, with the approval of blue light flexible cystoscopy bladder cancer surveillance can now be done in the clinic. The blue light cystoscopy with CYSVIEW is performed in the clinic to d...
|
- Details
- Yair Lotan discusses the recently published consensus statement on flexible blue light cystoscopy (BLC™) with Cysview ® . His presentation is centered around the published consensus in Nature Reviews developed by multiple experts (authors) in bladder cancer. Yair discusses the role of blue light flexible cystoscopy with CYSVIEW in non-muscle invasive bladder cancer. The expert consensus group met...
|
- Details
- Rebecca Roe speaks to an interdisciplinary approach to implementation of Blue Light Cystoscopy (BLC™) in her community hospital center, giving a Clinical Education Program Coordinator's perspective. Her team engaged in the five management practices looking at ongoing communication and clinical training and measured things along the way, seeking feedback from every discipline that was utilized, whe...
|
- Details
- Joshua Meeks joins Alicia Morgans to review his approach to cystoscopy using blue light and Cysview®, and how to best choose patients that will maximally benefit from that kind of technology. Dr. Meeks and Dr. Morgans also review the new approval of pembrolizumab in the BCG unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor...
|
- Details
- Stephen Williams discusses the macro and microeconomics of using blue light cystoscopy with CYSVIEW ® in nonmuscle invasive bladder cancer compared to white light cystoscopy alone. Dr. Williams notes that cancer care is expected to increase from $158 to $174 billion dollars between 2010 and 2020 due to increasing cancer incidence, improved survival outcomes, and an expanding healthcare market. Cos...
|
